A megfelelő beteg-együttműködés alapvető fontosságú minden terápia során. A beteg-együttműködés kifejezésére korábban a compliance meghatározás szolgált, amely azonban az orvos–beteg kapcsolat alá- és fölérendeltségét jelentette. Jelenleg az adherencia kifejezést használjuk, amely a beteg-együttműködés magasabb fokát jelenti, mivel feltételezi a beteg aktív közreműködését is. A betegek cardiovascularis terápia iránti adherenciája a fejlett országokban is csak mintegy 50%, ami azt jelenti, hogy a betegek fele nem szedi a számára felírt készítményeket. A gyógyszeres kezelés hiánya miatt e betegeknél növekszik a morbiditás és a mortalitás. A beteg-együttműködés hiányának számos oka lehet, és a betegek kezelése során ezekre is figyelemmel kell lennünk. Az adherencia javításával csökkenthető a szövődmények kialakulásának és a betegségprogresszió előrehaladásának a kockázata, amelyek összességében javítják az egészségi állapotot, és nem mellékesen csökkennek a betegre fordított egészségbiztosítási és társadalmi költségek is. Orv. Hetil., 2013, 154, 883–888.
Haynes, R. B., Ackloo, E., Sahota, N., et al.: Interventions for enhancing medication adherence. Cochrane Database Syst. Rev., 2008, 2, CD000011.
Sahota N. , 'Interventions for enhancing medication adherence ' (2008 ) 2 Cochrane Database Syst. Rev. : CD000011 -.
Norell, S. E.: Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc. Sci. Med. E., 1981, 15, 57–61.
Norell S. E. , 'Accuracy of patient interviews and estimates by clinical staff in determining medication compliance ' (1981 ) 15 Soc. Sci. Med. E. : 57 -61 .
Sumartojo, E.: When tuberculosis treatment fails. A social behavioral account of patient adherence. Am. Rev. Respir. Dis., 1993, 147, 1311–1320.
Sumartojo E. , 'When tuberculosis treatment fails. A social behavioral account of patient adherence ' (1993 ) 147 Am. Rev. Respir. Dis. : 1311 -1320 .
Morisky, D. E., Green, L. W., Levine, D. M.: Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care, 1986, 24, 67–74.
Levine D. M. , 'Concurrent and predictive validity of a self-reported measure of medication adherence ' (1986 ) 24 Med. Care : 67 -74 .
Aronson, J. K.: Compliance, concordance, adherence. Br. J. Clin. Pharmacol., 2007, 63, 383–384.
Aronson J. K. , 'Compliance, concordance, adherence ' (2007 ) 63 Br. J. Clin. Pharmacol. : 383 -384 .
Kane, S. V., Brixner, D., Rubin, D. T., et al.: The challenge of compliance and persistence: focus on ulcerative colitis. J. Manag. Care Pharm., 2008, 14 (Suppl. A), S2–S12.
Rubin D. T. , 'The challenge of compliance and persistence: focus on ulcerative colitis ' (2008 ) 14 J. Manag. Care Pharm. : S2 -S12 .
Vermeire, E., Hearnshaw, H., Van Royen, P., et al.: Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther., 2001, 26, 331–342.
Royen P. , 'Patient adherence to treatment: three decades of research. A comprehensive review ' (2001 ) 26 J. Clin. Pharm. Ther. : 331 -342 .
Gurwitz, J. H., Field, T. S., Harrold, L. R., et al.: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA, 2003, 289, 1107–1116.
Harrold L. R. , 'Incidence and preventability of adverse drug events among older persons in the ambulatory setting ' (2003 ) 289 JAMA : 1107 -1116 .
Heeschen, C., Hamm, C. W., Laufs, U., et al., Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation, 2002, 105, 1446–1452.
Laufs U. , 'Withdrawal of statins increases event rates in patients with acute coronary syndromes ' (2002 ) 105 Circulation : 1446 -1452 .
Foody, J. M., Joyce, A. T., Rudolph, A. E., et al.: Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr. Med. Res. Opin., 2008, 24, 1987–2000.
Rudolph A. E. , 'Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study ' (2008 ) 24 Curr. Med. Res. Opin. : 1987 -2000 .
Shepherd, J., Cobbe, S. M., Ford, I., et al., for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 1995, 333, 1301–1307.
Ford I. , 'Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia ' (1995 ) 333 N. Engl. J. Med. : 1301 -1307 .
Bradford, R. H., Shear, C. L., Chremos, A. N., et al.: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med., 1991, 151, 43–49.
Chremos A. N. , 'Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia ' (1991 ) 151 Arch. Intern. Med. : 43 -49 .
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364, 685–696.
Durrington P. N. , 'Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial ' (2004 ) 364 Lancet : 685 -696 .
Sever, P. S., Dahlöf, B., Poulter, N. R., et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT – LLA): a multicentre randomised controlled trial. Lancet, 2003, 361, 1149–1158.
Poulter N. R. , 'Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT – LLA): a multicentre randomised controlled trial ' (2003 ) 361 Lancet : 1149 -1158 .
Downs, J. R., Clearfield, M., Weis, S., et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279, 1615–1622.
Weis S. , 'Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study ' (1998 ) 279 JAMA : 1615 -1622 .
Jermendy, Gy., Wittman, I., Nagy, L., et al.: Persistence of oral antidiabetic therapy in diabetic patients in Hungary between 2007 and 2009 years. [Az orális antidiabetikum-terápia perzisztenciája hazai cukorbetegek körében, 2007–2009 között.] Metabolizmus, 2011, 9, 21–27. [Hungarian]
Nagy L. , 'Persistence of oral antidiabetic therapy in diabetic patients in Hungary between 2007 and 2009 years. [Az orális antidiabetikum-terápia perzisztenciája hazai cukorbetegek körében, 2007–2009 között.] ' (2011 ) 9 Metabolizmus : 21 -27 .
Kravitz, R. L., Hays, R. D., Sherbourne, C. D., et al.: Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch. Intern. Med., 1993, 153, 1869–1878.
Sherbourne C. D. , 'Recall of recommendations and adherence to advice among patients with chronic medical conditions ' (1993 ) 153 Arch. Intern. Med. : 1869 -1878 .
Newby, L. K., LaPointe, N. M., Chen, A. Y., et al.: Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 2006, 113, 203–212.
Chen A. Y. , 'Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease ' (2006 ) 113 Circulation : 203 -212 .
Jackevicius, C. A., Li, P., Tu., J. V.: Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation, 2008, 117, 1028–1036.
Tu. J. V. , 'Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction ' (2008 ) 117 Circulation : 1028 -1036 .
Simpson, S. H., Eurich, D. T., Majumdar, S. R., et al.: A meta-analysis of the association between adherence to drug therapy and mortality. Br. Med. J., 2006, 333 (7557), 15. Epub 2006 Jun 21.
Majumdar S. R. , 'A meta-analysis of the association between adherence to drug therapy and mortality ' (2006 ) 333 Br. Med. J. : 15 -.
Mazzaglia, G., Ambrosioni, E., Alacqua, M., et al.: Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation, 2009, 120, 1598–1605.
Alacqua M. , 'Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients ' (2009 ) 120 Circulation : 1598 -1605 .
Wogen, J., Kreilick, C. A., Livornese, R. C., et al.: Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J. Manag. Care Pharm., 2003, 9, 424–429.
Livornese R. C. , 'Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting ' (2003 ) 9 J. Manag. Care Pharm. : 424 -429 .
Dankó, D.: Factorts behind patient cooperation. [A beteg-együttműködés mögött meghúzódó tényezők.] Medical Tribune, 2010, 8, 5. [Hungarian]
Dankó D. , 'Factorts behind patient cooperation. [A beteg-együttműködés mögött meghúzódó tényezők.] ' (2010 ) 8 Medical Tribune : 5 -.
Molnár, M. P., Dankó, D.: Patients cooperation as a key of therapeutic success. [A beteg-együttműködés a terápiás siker záloga.] Orvostovábbképző Szemle, 2010, 16, 13–19. [Hungarian]
Dankó D. , 'Patients cooperation as a key of therapeutic success. [A beteg-együttműködés a terápiás siker záloga.] ' (2010 ) 16 Orvostovábbképző Szemle : 13 -19 .